Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Major US defence company sets up in SA

TNA's industrial XR brings Industry 5.0 to food manufacturers

Queensland boosting local manufacturing

Hazer completes testing of its commercial demonstration plant

Anticipating maintenance problems with predictive analytics

NSW celebrates recycling triumph

REMONDIS expands into Western Qld

From coal to clean: accelerating Asia's renewable energy transition

Experts call for fashion waste overhaul

Mitigating cybersecurity risks in tomorrow's smart cities

High blood pressure costs Australia $1.2bn a year

A Day in the Life of Mater Midwife Gabby Rowsell

Healthscope terminates Bupa, AHSA contracts

Govt appoints nine members to drive health tech reform

Nine nursing and midwifery organisations form an Alliance

Lonza bone marrow and cord blood mononuclear cells

Lumiprobe DusQ fluorescence quenchers

Enzo Life Sciences SCREEN-WELL Epigenetics library

LSBio PathPlus Cancer Antibodies

Content from other channels on our network